| Douglas C Shook, MD | |
|
75 Francis Street, Brigham And Women's Hospital Department Of Anesthesia, Boston, MA 02115 | |
| (617) 732-8210 | |
| Not Available |
| Full Name | Douglas C Shook |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 27 Years |
| Location | 75 Francis Street, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154388429 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 219121 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Brigham And Women's Hospital | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Brigham And Women's Physicians Organization Inc | 3870405988 | 2510 |
News Archive
Increased stress levels, sleep disorders and obesity have become hallmarks of present lifestyle. These conditions are often correlated with serious health problems such as cancer, diabetes, cerebral ischemia, stroke, etc.
"As Congress wrangles with overhauling the health care system, there is one population not being discussed. No proposal for a national health plan would cover the nation's estimated 11 million illegal immigrants," NPR reports.
A new study, by two Goethe University Frankfurt researchers, published on the preprint server medRxiv* in September 2020 explores the relationship between the monsoon season, the chances of exposure to ultraviolet B (UVB) radiation, and the COVID-19 mortality.
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.
Soligenix, Inc., a late-stage biopharmaceutical company, announced today that it has entered into common stock purchase agreements with both existing and new investors totaling approximately $5.16 million. Soligenix's North American commercial partner, Sigma-Tau Pharmaceuticals, Inc., participated in this financing.
› Verified 7 days ago
| Entity Name | Brigham And Women's Physicians Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033535497 PECOS PAC ID: 3870405988 Enrollment ID: O20150107001260 |
News Archive
Increased stress levels, sleep disorders and obesity have become hallmarks of present lifestyle. These conditions are often correlated with serious health problems such as cancer, diabetes, cerebral ischemia, stroke, etc.
"As Congress wrangles with overhauling the health care system, there is one population not being discussed. No proposal for a national health plan would cover the nation's estimated 11 million illegal immigrants," NPR reports.
A new study, by two Goethe University Frankfurt researchers, published on the preprint server medRxiv* in September 2020 explores the relationship between the monsoon season, the chances of exposure to ultraviolet B (UVB) radiation, and the COVID-19 mortality.
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.
Soligenix, Inc., a late-stage biopharmaceutical company, announced today that it has entered into common stock purchase agreements with both existing and new investors totaling approximately $5.16 million. Soligenix's North American commercial partner, Sigma-Tau Pharmaceuticals, Inc., participated in this financing.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Douglas C Shook, MD 75 Francis Street, Brigham And Women's Hospital Department Of Anesthesia, Boston, MA 02115 Ph: (617) 732-8210 | Douglas C Shook, MD 75 Francis Street, Brigham And Women's Hospital Department Of Anesthesia, Boston, MA 02115 Ph: (617) 732-8210 |
News Archive
Increased stress levels, sleep disorders and obesity have become hallmarks of present lifestyle. These conditions are often correlated with serious health problems such as cancer, diabetes, cerebral ischemia, stroke, etc.
"As Congress wrangles with overhauling the health care system, there is one population not being discussed. No proposal for a national health plan would cover the nation's estimated 11 million illegal immigrants," NPR reports.
A new study, by two Goethe University Frankfurt researchers, published on the preprint server medRxiv* in September 2020 explores the relationship between the monsoon season, the chances of exposure to ultraviolet B (UVB) radiation, and the COVID-19 mortality.
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.
Soligenix, Inc., a late-stage biopharmaceutical company, announced today that it has entered into common stock purchase agreements with both existing and new investors totaling approximately $5.16 million. Soligenix's North American commercial partner, Sigma-Tau Pharmaceuticals, Inc., participated in this financing.
› Verified 7 days ago
Stephen G. Flynn, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 300 Longwood Ave, Boston, MA 02115 Phone: 617-355-6000 | |
Dr. Dusan Hanidziar, M.D., PH.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 55 Fruit St, Gray-bigelow 444, Boston, MA 02114 Phone: 617-726-3030 | |
Dr. Michael Christopher Lubrano, M.D., M.P.H. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Boston, MA 02115 Phone: 617-732-8210 | |
Vahid Kiarad, M.D Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 330 Brookline Ave, Boston, MA 02215 Phone: 617-667-7000 | |
Kendrick M Shaw, MD, PHD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114 Phone: 617-726-3030 | |
John William Carl Carter Mallett, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 75 Francis St, Boston, MA 02115 Phone: 617-732-5500 | |
Dr. David Joswick, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 800 Washington St, Boston, MA 02111 Phone: 617-636-5000 |